France Antifungal Drugs Market Analysis Report 2022 to 2030

France Antifungal Drugs Market Analysis

$ 3999

France Antifungal Drugs Market is at around $0.43 Bn in 2023 and is projected to reach $0.53 Bn in 2030, exhibiting a CAGR of 2.8% during the forecast period. The market is expanding due to factors such as rising awareness and education, advancements in healthcare infrastructure, and an increase in the incidence of fungal infections. The market is dominated by key players like Pfizer Inc., Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.

ID: IN10FRPH004 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Aneri Parekh

Buy Now

France Antifungal Drugs Market Executive Summary

France Antifungal Drugs Market is at around $0.43 Bn in 2023 and is projected to reach $0.53 Bn in 2030, exhibiting a CAGR of 2.8% during the forecast period.

The French market for Antifungal drugs is committed to the manufacturing, distribution, and use of drugs intended to treat fungal infections in the country's healthcare system. This market includes a variety of antifungal drugs that address the different demands of patients in different healthcare environments, such as topical creams, oral pills, and intravenous formulations. The dynamic environment of this market in France is influenced by elements such as changing healthcare legislation, growing rates of fungal infections, and advances in drug research.

The market for antifungal drugs in France is expanding steadily, propelled by growing awareness and an increase in the frequency of fungal diseases. To increase their market share and provide cutting-edge treatment choices, major players are concentrating on innovation and strategic alliances. Regulations and healthcare reforms are still influencing market dynamics and reshaping the antifungal medicine industry's competitive environment.

Global sales of antifungal medications were estimated to be $15.8 Bn in 2023. Notable advancements in antifungal therapy have been brought about by improvements in therapeutic efficacy and availability. The sector for antifungal medications has also experienced a lot of investment, which has been crucial to sustaining the high growth trend in the field. The market for antifungal medications is very promising and is characterized by more production, increasing profitability, and enhanced industrial innovation.

Pfizer is the market leader in France with about 25–30% of the antifungal market. In France, Pfizer sold antifungal medications for over 270 Mn in 2020. Pfizer invests in marketing and patient education programs, highlighting Vfend as its flagship product, and in collaboration with Basilea, works on Cresemba marketing and distribution throughout Europe.

France antifungal drugs market

Market Dynamics

Market Growth Drivers:

Growing Prevalence of Fungal Infections: The need for Antifungal medications is driven by the growing incidence of fungal infections in elderly people, immunocompromised patients, and people with chronic illnesses.

Improvements in Healthcare Infrastructure: The need for Antifungal medications is raised by the increasing detection and treatment of fungal infections, which is facilitated by improved diagnostics, access to healthcare facilities, and healthcare infrastructure.

Growing Knowledge and Awareness: Prescription rates for Antifungal drugs rise as a result of growing patient and healthcare professional awareness of the value of treating fungal infections as soon as possible.

Market Restraints:

Preference for Alternative Therapies: The market potential may be limited if consumers and healthcare professionals favor alternative therapies like homeopathy or natural remedies over prescription Antifungal medications.

Side Effects and Safety Concerns: Antifungal medications, like any other prescription, may have side effects and safety concerns. These issues may discourage patients and healthcare professionals from utilizing antifungal medications, particularly in cases of moderate or superficial fungal infections.

High Treatment Cost: For some patients, the cost of certain antifungal medications may be unaffordable, especially if they do not have sufficient insurance or if the healthcare system does not pay for the medications. This may restrict access to care and impede market expansion.

Healthcare Policies and Regulatory Landscape

The Agence nationale de sécurité du médicament et des produits de santé (ANSM) is a public institution that operates under the Ministry of Health's administration. It provides access to cutting-edge treatments and ensures the security of medical supplies on behalf of the French government. ANSM inspectors have the power to impose different enforcement actions and monitor compliance with pertinent rules and regulations through audits and inspections. The European Medicines Agency (EMA) partnership facilitates a more sophisticated centralized approvals process that requires adherence to both national and EU regulatory standards. The process of bargaining for compensation following approval contributes to the overall complexity of French drug approval.

Competitive Landscape

Key Players:

Pfizer Inc.
Abbott Laboratories
Merck & Co., Inc.
Astellas Pharma Inc.
GlaxoSmithKline plc
Bayer AG
Novartis AG
Glenmark Pharmaceuticals Limited
Sanofi S.A.
Gilead Sciences Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

France Antifungal Drugs Market Segmentation

By Drug Class

Azoles
Echinocandins
Polyenes
Allylamines
Others

By Drug Indication

Dermatophytosis
Aspergillosis
Candidiasis
Others

By Drug Dosage

Oral drugs
Ointments
Powders
Others

By Infection

Systemic Antifungal Infections
Superficial Antifungal Infections

By Drug Distribution

Hospital Pharmacies
Retail Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.